Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia

Core-binding factor acute myeloid leukemia is characterized by t(8;21) or inv(16) and the fusion proteins RUNX1-RUNX1T1 and CBFB-MYH11. International guidelines recommend monitoring for measurable residual disease every 3 months for 2 years after treatment. However, it is unknown if serial molecula...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Robert Puckrin, Eshetu G. Atenafu, Jaime O. Claudio, Steven Chan, Vikas Gupta, Dawn Maze, Caroline McNamara, Tracy Murphy, Andre C. Shuh, Karen Yee, Hassan Sibai, Mark D. Minden, Cuihong Wei, Tracy Stockley, Suzanne Kamel-Reid, Aaron D. Schimmer
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Ferrata Storti Foundation 2020-01-01
Serie:	Haematologica
Länkar:	https://haematologica.org/article/view/9590
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!